论文部分内容阅读
R-81001是医科院药物所新合成的维甲类衍生物,分子量为454.63。经实验证明它对亚硝胺诱发的小鼠前胃上皮增生癌变有明显的抑制作用,而且它的毒性较同类其他衍生物均低。为探讨其作用原理以及对临床应用可能有指导意义的用药方式,我们用电镜组化方法,从超微结构水平结合细胞生长曲线,研究了R-81001对人早幼粒白血病细胞株(HL-60)的作用,同时进行了联合用药的研究。HL-60细胞培养在RPMI—1640培养液中,加10％小牛血清及适量抗菌素。收集对数生长期的细胞,以2×10~5ml的细胞悬液每瓶5mcl分装在培养瓶内。按种细胞的同时给药。实验分1％DMSO组,1×10~(-6)M-R-81001组,1％OMSO加1×10~(-6)MR-81001联合给药组以及不加上述任何药物的对照组。
R-81001 is a newly synthesized vitamin A derivative from Institute of Materia Medica, with a molecular weight of 454.63. It has been proved by experiments that nitrosamine-induced mouse anterior gastric epithelial hyperplasia cancerous significantly inhibited, and its toxicity than other similar derivatives are low. In order to explore the principle of its action and its possible clinical application, we studied the effect of R-81001 on human promyelocytic leukemia cell line (HL- 60) the role of the same time, the study of combination therapy. HL-60 cells were cultured in RPMI-1640 medium supplemented with 10% calf serum and appropriate amount of antibiotics. Collect cells in logarithmic growth phase and dispense 2 × 10 ~ 5ml of cell suspension into 5ml flask. The same time by the kinds of cells administered. The experimental group was divided into 1% DMSO group, 1 × 10 -6 M-R-81001 group, 1% OMSO plus 1 × 10 -6 MR-81001 combination group and control group without any drug.